Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
F. Wang, K. Morita, C. DiNardo…·K. Takahashi
The paper identifies leukemia stemness and co-occurring mutations as drivers of resistance to IDH inhibitors in AML through genomic analyses of treated patients.